Microcap Ledger Citius Pharmaceuticals, Inc. $CTXR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cranford, NJ
- Fiscal year end
- September 30
- Shares outstanding
- 27,452,570 [10-Q 2026-08-14]
What the company doesAI summary of filing
Citius Pharmaceuticals is a biopharmaceutical company developing and commercializing pharmaceutical products for critical care, oncology, and anti-infectives. The company became revenue-generating in December 2025 with the launch of LYMPHIR (denileukin diftitox), an FDA-approved treatment for cutaneous T-cell lymphoma, through its majority-owned subsidiary Citius Oncology. Citius also has late-stage product candidates in development including Mino-Lok for catheter-related bloodstream infections, Halo-Lido for hemorrhoids, and NoveCite, a mesenchymal stem cell therapy for acute respiratory disease syndrome. The company makes money through product commercialization and licensing agreements, with LYMPHIR generating its initial commercial revenues. [10-K 2025-12-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | $7.11M | −$49.42M | −$22.99M | $17.01M | [10-Q 2026-08-14] |
| FY ended Sep 2025 | — | −$39.74M | −$26.55M | $4.25M | [10-K 2025-12-23] |
| FY ended Sep 2024 | — | −$39.43M | −$28.20M | $3.25M | [10-K 2025-12-23] |
- Quarterly cash burn
- −$7.66M
- Cash runway Estimate
- ~6.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-18 | 7,727,243 | [10-K/A 2025-01-27] |
| 2025-02-11 | 8,593,433 | [10-Q 2025-02-14] |
| 2025-05-09 | 10,290,335 | [10-Q 2025-05-14] |
| 2025-08-11 | 17,012,191 | [10-Q 2025-08-12] |
| 2025-12-17 | 20,762,917 | [10-K/A 2026-01-28] |
| 2026-02-10 | 22,376,427 | [10-Q 2026-02-13] |
| 2026-05-14 | 27,452,570 | [10-Q 2026-05-15] |
| 2026-08-13 | 27,452,570 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-05-22; declared effective 2026-06-02 [S-3 2026-05-22]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-21] |
| 2026-02-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-13] |
| 2025-05-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-30] |
| 2024-11-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-21 | 8-K | Listing notice or transfer |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 8-K | Other events |
| 2026-06-04 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-01 | 8-K | Other events |
| 2026-05-22 | S-3 | Registration statement |
| 2026-05-15 | 8-K | Results of operations |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-08 | 8-K | Material agreement entered |
| 2026-04-29 | 8-K | Unregistered sale of equity; Other events |
Alerts for $CTXR
Email me when Citius Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.